Kudalkar, Emily M.
Pang, Changlee
Haag, Mary M.
Pollyea, Daniel A.
Kamdar, Manali
Xu, Gang
Su, Meng
Carstens, Billie
Swisshelm, Karen
Bao, Liming
Funding for this research was provided by:
National Cancer Institute (P30CA046934)
Article History
Received: 6 May 2022
Accepted: 20 June 2022
First Online: 7 July 2022
Declarations
:
: This study was approved by the Colorado Multiple Institutional Review Board in accordance with the Declaration of Helsinki. The Colorado Multiple Institutional Review Board has determined this as a chart review case study and granted wavier of informed consent based on its policy.
: Emily M. Kudalkar, Changlee Pang, Mary M. Haag, Daniel A. Pollyea, Gang Xu, Billie Carstens, Karen Swisshelm and Liming Bao declare they have no competing interests. Manali Kamdar reports research funding from TG Therapeutics, Genentech, Novartis; Consultancy from AbbVie, AstraZeneca, Celgene/ Bristol-Myers Squibb, Adaptive Biotechnologies, ADC therapeutics, Beigene; Speaker's bureau for SeaGen and DMC for Celgene, Genentech. Meng Su is currently a salaried employee of Sema4 OpCo, Inc.